Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 159 resultados

SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

PROCRYSTAL: Crystallisation towards efficient and sustainable biomanufacturing JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 "Downstream processing (DSP) of biopharmaceuticals is dominated by chromatographic steps which suffer from low throughput, poor scalability...
2024-07-10 - 2028-12-31 | Financiado

NextBase: Base metal-catalytic cross-coupling methodologies towards sustainability JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 "Catalysis is today exploited for preparing ca. 90% of chemical and pharmaceutical products. Use of catalysts allows for efficient chemical...
2023-06-29 - 2027-09-30 | Financiado

IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado

CTCAN: Clinical Trials Community Africa Network JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 With over 25% of the global disease burden, only 3% of global clinical trials occur in Africa. This disproportion is driven by inadequacies...
2023-05-02 - 2025-10-31 | Financiado

DICE: DIgital health in Circular Economy JANSSEN PHARMACEUTICA NV tramitó un HORIZON EUROPE: HORIZON-CL6-2021-CIRCBIO-01 DICE aims to develop and demonstrate novel, circular and environmentally sound solutions to design, collect, directly reuse, refurbish, rema...
2022-10-01 - 2026-09-30 | Financiado

RM ROADMAP: CREATING FRAMEWORK CONDITIONS FOR RESEARCH MANAGEMENT TO STRENGTHEN THE EUROPEAN RESEARCH AREA JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-WIDERA-2021-ERA-01 RM ROADMAP (Creating Framework Conditions for Research Management to Strengthen the European Research Area) will create a roadmap for the fu...
2022-05-20 - 2025-08-31 | Financiado

GENEGUT: Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease JANSSEN PHARMACEUTICA NV participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 Crohn’s disease is a non-communicable, global disease with an accelerating incidence (up to 23 per 100,000 persons/year) and annual health c...
2022-05-19 - 2026-09-30 | Financiado

EPND: European platform for neurodegenerative disorders JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a la...
2021-10-25 - 2026-10-31 | Financiado

BEAMER: BEhavioral and Adherence Model for improving quality health outcomes and cost Effectiveness of heal... JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outco...
2021-09-27 - 2026-08-31 | Financiado

UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for...
2021-06-29 - 2028-05-31 | Financiado

ALLODD: Allostery in Drug Discovery JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-MSCA-ITN-2020 Most current drugs are designed to bind directly to the primary active sites (also known as orthosteric sites) of their biological targets....
2021-05-28 - 2025-08-31 | Financiado

PROMISE: Preparing for RSV Immunisation and Surveillance in Europe JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado

REALMENT: Using real world big data from eHealth biobanks and national registries integrated with clinical t... JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-SC1-BHC-2018-2020 Mental disorders represent one of the largest burdens for the European Health Care system, due to large number of patients and a lack of eff...
2021-01-29 - 2025-11-30 | Financiado

BIGPICTURE: Central Repository for Digital Pathology JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado

Gravitate-Health: Gravitate Health Empowering and Equipping Europeans with health information for Active Personal Hea... The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsiv...
2020-11-12 - 2025-10-31 | Financiado

ARDAT: Accelerating Research Development for Advanced Therapies JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado

InPharma: A fully integrated animal free end to end modelling approach to oral drug product development JANSSEN PHARMACEUTICA NV participó en un H2020: H2020-MSCA-ITN-2020 Oral drug products are preferred by hundreds of millions of patients in Europe. Yet, the challenges around formulating drugs for oral admini...
2020-09-07 - 2024-12-31 | Financiado